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Abstract 
Background: Concurrent extrahepatic autoimmune disease (CEHAID) associated with 
autoimmune hepatitis (AIH) have been incorporated into the diagnostic criteria stipulated by 
the International Autoimmune Hepatitis Group (IAIHG). Large comprehensive cohort data 
on the extrahepatic autoimmunity in AIH remain scanty. Aim: To systematically assess 
features and clinical impact of CEHAID on AIH. Methods: Clinical records of 562 patients 
with AIH from two tertiary centres in the United Kingdom were retrospectively reviewed. 
Results: Prevalence of CEHAID in patients with AIH were 42%. Autoimmune thyroid 
disease was the commonest CEHAID associated with AIH (101/562, 18%). Autoimmune 
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skin diseases were more prevalent in AIH-2 than AIH-1 (21.9% vs.7%, p=0.009). Personal 
history of CEHAID was more commonly found in AIH patients with than without first degree 
family history of CEHAID [(48/86, 55.8% vs 169/446, 37.9%), p=0.002]. AIH patients with 
CEHAID were more often female [201/236 (85.2%), p=0.008], had higher post-treatment 
IAIHG score (22 vs. 20, p<0.001), less reactivity to smooth muscle antibodies (49.8% vs 
65%, p<0.001), more likely to have mild fibrosis at diagnosis (20.9% vs. 6.5%, p<0.001), less 
often had ascites (6.3% vs. 13.6%, p=0.008) and coagulopathy (1.18 vs. 1.27, p=0.013) at 
presentation. Presence of CEHAID, however, did not significantly affect disease progression, 
prognosis and survival in AIH. Conclusions: Our study confirms the strong association of 
CEHAID with AIH. Association between personal and familial extrahepatic autoimmunity 
especially among first degree relatives was evident. Presence of CEHAID may influence 
clinical phenotype of AIH at presentation but without notable impact on the long term clinical 
outcomes. 
 
Key words: Autoimmune thyroiditis, autoimmune skin disease, extrahepatic autoimmune 
diseases, family history, first degree relatives 
 
Key Points  
• This is the largest cohort study to systematically assess patterns and clinical impact of 
CEHAID in AIH.  
 
• AIH is strongly associated with CEHAID. Autoimmune skin diseases were more 
prevalent in AIH-2 than AIH-1. 
• This study reinforces the close association of extrahepatic autoimmunity among AIH 
patients and their family particularly first degree relatives. 
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• This is the first study to observe that presence of CEHAID may influence the 
reactivity of the circulating smooth muscle antibodies and effect the clinical 
phenotype of AIH at index presentation, albeit, without seeming to impact on disease 
progression and clinical outcomes. 
 
Introduction 
Autoimmune hepaitits (AIH) is an immune-mediated liver disease which can present 
in acute or chronic forms, and may lead to cirrhosis and liver failure if untreated. It is 
characterised by elevated transaminases, raised Immunoglobulin G levels, histological 
features of interface hepatitis with a lymphoplasmacytic infiltration and the presence of 
autoantibodies in serum (1–3).   
The diagnosis and management of AIH could be challenging as AIH represents a 
chameleon disease with protean clinical manifestation and significant heterogeneity in 
relation to clinical course and outcome. Indeed, the clinical features are not confined to the 
liver. Concurrent extrahepatic autoimmune disorders (CEHAID) including autoimmune 
thyroiditis, connective tissue disease and inflammatory bowel disease are frequently 
associated with AIH. CEHAID may predate, coincide or even occur years after the diagnosis 
of AIH. This association has been recognised and incorporated into the original and revised 
International Autoimmune Hepatitis Group (IAIHG) scoring systems as an aid to codifing the 
diagnosis (4,5). The frequency of CEHAID in AIH has been derived predominantly from 
case reports (6–12) and a few cohort studies (13–15).  Large cohort studies to systematically 
assess the features and effect of CEHAID in AIH are lacking.  
On the other aspect, since AIH arises in genetically susceptible individuals, there may 
be a close relationship between personal and familial hepatic and extrahepatic autoimmunity. 
Although up to 43% of AIH patients have been reported to have a family history of CEHAID 
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in their first degree relatives, commonly with thyroid disease and type 1 diabetes (16,17), the 
association of extrahepatic autoimmunity among AIH patients and their family especially 
first degree relatives remains unexplored. 
In this study, we sought to describe the patterns of CEHAID, the association of 
personal and familial extrahepatic autoimmunity in AIH and finally to evaluate the impact of 
CEHAID, if any, on the clinical course and long term outcomes. 
 
Patients and Methods 
Two well-established and updated databases of patients with AIH attending the 
Institute of Liver studies at King’s College Hospital, London between 1971 and October 
2015, and the Department of Hepatology, Brighton and Sussex University Hospital, Brighton 
between January 2005 and June 2014 were reviewed. A total of 562 consecutive patients with 
AIH were identified [455 definite AIH, median post treatment IAIHG score 21 (18-28) and 
107 probable AIH, median post treatment score 16 (11-17)]. The diagnosis of AIH was made 
based on the revised IAIHG scoring system (5). Median duration of follow-up was 123 
months (0.5-544). Patients’ records were systematically reviewed and examined with regards 
to the frequency and patterns of CEHAID as well as the association between personal and 
family history of CEHAID among AIH patients and their first and second degree relatives. 
Finally, two groups of AIH patients with and without CEHAID were compared in relation to 
the clinical, laboratory and histological features, response to therapy, clinical outcomes and 
survival.  
As described in our previous studies, standard diagnostic criteria for the presence of 
AIH was fulfilled (18–20). There was no corroborative history of concomitant use of 
hepatotoxic drugs except for eleven patients who had diagnosis of drug-induced AIH (20). 
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Liver biopsy was available at diagnosis in 471(83.8%) of 562 patients with AIH. Histological 
assessment of the severity of liver inflammation and the degree of fibrosis was based on the 
scoring system proposed by Batts and Ludwig (21).  In this system, necroinflammatory 
activity is graded as 0 = none, 1= minimal, 2 = mild, 3 = moderate and 4 = marked activity  
+/- bridging collapse or multiacinar necrosis, whereas the degree of fibrosis is staged as 0 = 
none, 1 = portal, 2 = periportal, 3 = septal/bridging fibrosis including incomplete cirrhosis 
and 4 = cirrhosis. 
AIH-1 was defined by the presence of antinuclear antibody (ANA) or smooth muscle 
antibody (SMA) or both. AIH-2 and autoantibody negative AIH were classified by the 
presence of anti-liver-kidney microsomal-1 (anti-LKM1) and absence of all the 
autoantibodies described respectively.  
Associated diagnosis of CEHAID and family history of autoimmune diseases were 
searched and retrieved via the the hospital electronic records, clinical letters and medical 
casenotes. All these diseases have been diagnosed and confirmed based on the international 
criteria, when available. 
Time to diagnosis was defined as the time from the first onset of symptoms or first 
detection of liver dysfunction to the formal diagnosis of AIH. The mode of presentation 
refered to the acuity of the initial illness or symtomatology, and was defined as ‘acute’ if 
symptom onset to diagnosis was ≤ 6 months, ‘insidious’> 6 months and ‘asymptomatic’ if  
the patients had no obvious signs or symptoms of liver disease and the diagnosis of AIH was 
first discovered based on the incidental finding of abnormal liver tests either during routine 
health screening or during evaluation of a non-hepatic illness.  Follow-up duration was 
defined as the time of the diagnosis was first made until the last outpatient appointment in the 
clinic, or death or liver transplantation (LT) (18,19).  
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All patients with AIH were treated according to standardised protocols published 
previously (18,19,22). Response to treatment and relapse were defined in accordance with the 
revised criteria of the IAIHG (5), and partial or no response to initial therapy according to the 
original criteria (4).  
 
Disease progression was defined as the development of cirrhosis in non-cirrhotic 
patients based on imaging and/or histology during follow-up, worsening of the fibrosis scores 
on repeat histology, when available, despite on optimum immuosuppression, and the 
occurrence of clinically significant liver-related complications including episodes of 
decompensation, development of hepatocellular carcinoma (HCC), death or LT in cirrhotic 
patients.  
This study was approved by the Research Ethics Committee of King’s College 
Hospital (04/Q0703/23) and is part of an ongoing research project in AIH for which patients 
have given informed consent.  
 
Statistical analysis 
Results were analysed using SPSS version 21.0 (IBM Corp, Armonk NY). 
Continuous variables were expressed as median (range). Categorical variables are expressed 
as actual numbers and percentages. Analysis of variance was used to compare the differences 
in variable between the two groups. Group comparisons of categorical variables were 
analysed with χ2-test or Fisher’s exact test if the expected cell frequency is less than 5. The 
Mann–Whitney test was used for the evaluation of continuous variables.  
End-points and censoring date for survival analysis were taken as the time of most 
recent clinic visit or date of death or LT. Death from complications of cirrhosis, progressive 
liver failure and HCC were considered to be liver-related. Survival rates between 2 groups of 
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AIH patients with and without CEHAID were calculated according to the Kaplan-Meier 
method and compared using the log-rank test. Univariate analysis using Cox’s proportional 
hazards regression model for survival analysis was adopted to assess the predictive value of a 
number of variables on survival outcome. This was followed by multivariate analysis to 
identify independent predictors of adverse outcome. A value of P < 0.05 was considered to be 
statistically significant. Missing data were <10% in all categories (except where specified, i.e. 
histology and variables for clinical outcomes) and were excluded on a per-analysis basis. 
 
Results 
Frequency of CEHAID in AIH  
Two hundred and thirty-six of 562 AIH patients (42%) had at least one associated 
CEHAID. Among these, 168 (29.9%) had one associated CEHAID, 53 (9.4%) had two, 10 
(1.8%) had three, 3 (0.5%) had four, and one each had five and seven associated CEHAIDs 
respectively (Fig. 1).   
In total, 58 different diagnoses of CEHAID were identified. Of these, 26/253(10.2%), 
89/253(35.2%) and 138/253(54.6%) were diagnosed at presentation, during the follow-up and 
preceding the diagnosis of AIH, respectively. The chronological diagnosis of 75 CEHAIDs in 
relation to the diagnosis of AIH were uncertain. The frequency of associated CEHAID in 
AIH was depicted in Table 1. Other rarer CEHAIDs are not shown. 
 
Family History of concurrent hepatic and CEHAID in AIH  
A positive family history of CEHAID was identified in 92/532 (17.3%) patients with 
AIH, and of these, 51/92 (55.4%) had concurrent extrahepatic autoimmunity in their personal 
history. This was significantly more prevalent when compared to patients without family 
history of CEHAID, 166/440 (37.7%) (p=0.002).  Eighty-six patients (86/532, 16.2%) with a 
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positive family history had at least one first degree relative with an associated CEHAID. 
Amongst these, 57/86 (66.2%) had one first degree relative with CEHAID, 22/86 (25.6%) 
had two,  4 (4.7%) had three, 2 (2.3%) had four and one (1.2%) had six first degree relatives 
with CEHAID. In the same context, personal history of CEHAID was more commonly found 
in AIH patients with than without first degree family history of CEHAID [(48/86, 55.8% vs 
169/446, 37.9%), p=0.002]. A postive family history of CEHAID amongst second degree 
relatives was also present in 14 AIH patients (2.6%) but there was no significant difference 
between patients with and without extrahepatic autoimmunity in their personal history [9/14 
(64.3%) vs.  208/518 (40.2%), p=0.070].  
The most common CEHAID among family members was thyroid disease (45/92, 
48.9%) followed by diabetes mellitus (26/92, 28.2%), connective tissue disorders (21/92, 
22.8%) and  autoimmune skin disease (8/92, 8.7%). The prevalence of a family history of an 
autoimmune liver disease in AIH cohort was 7/532 (1.3%). Family history of AIH and PBC 
was found in 4 patients (0.75%) and 3 patients (0.56%), respectively.  
 
Clinical patterns of CEHAID in AIH  
Autoimmune thyroid disease (AITD) was the commonest CEHAID in AIH patients 
(18%), followed by connective tissue disorders (12.3%) and autoimmune skin diseases (8%) 
(Table 1). Hypothyroidism was more prevalent than hyperthyroidism [79/101 (78.2%) vs 
22/101 (21.8%), p<0.001].  Based on the serological subtypes of AIH (Table 2), AITD were 
more common in AIH-2 and autoantibody negative AIH than AIH-1 (31.1% vs 15.9% and 
32% vs 15.9% respectively, p<0.05). Hyperthyroidism was more prevalent in AIH-2 (12.5 vs 
3.1%, p=0.024) whereas hypothyroidism was more common in autoantibody negative AIH 
than AIH-1 (25% vs 12.9%, p=0.014). Interestingly, autoimmune skin lesions were more 
frequently diagnosed in AIH-2 than AIH-1 (21.9% vs 7%, p=0.009). The main skin lesions in 
AIH-2 included vitiligo, leucocytoclastic vasculitis, urticaria and alopecia areata.  
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Impact of CEHAID on the clinical course and outcome of AIH  
Tables 3 and 4 illustrate the demographics, clinical presentation, biochemical and 
histological aspects of AIH patients with and without CEHAID. Women were more likely to 
have CEHAID than men (201/248, 81% vs 35/79, 44.8%, p=0.008). Interestingly, AIH 
patients with CEHAID had lower occurence of ascites and had less prolonged protrombin 
time/International Normalised ratio (INR) at presentation (6.3% vs. 13.6%, p=0.008 and 1.18 
vs. 1.27, p=0.013), respectively. Moreover, AIH patients with CEHAID frequently had mild 
fibrosis (stage 1) on histology at diagnosis when compared to patients without CEHAID 
[(28/134 (20.9%) vs. 13/200 (6.5%), p<0.001]. There was, however, no difference in terms of 
severity of the histological inflammation at diagnosis between the 2 groups. The incidence of 
cirrhosis at presentation (based on histology and /or imaging studies) did not differ 
significantly between AIH patients with and without CEHAID (31% vs. 35.6% p=0.261). 
The coexistence of associated CEHAID was also independent of the modes of presentation.   
 
Patients with CEHAID tended to have joint pain as their index presentation compared 
to their counterparts without CEHAID [18/221 (8.1%) vs. 9/295 (3.1%), p=0.01]. The 
frequency of ANA positivity did not differ significantly in the presence of CEHAID. 
Nonetheless, the median peak ANA titre was significantly higher in patients with CEHAID 
(1:80 vs 1:40, p <0.001). In contrast, SMA positivity was more prevalent in AIH patients 
without CEHAID (65.1% vs 49.8%, p<0.001). Further analysis revealed a higher proportion 
of patients without CEHAID had a median SMA titre of >1:80 (41.2% vs 30%, p=0.009) and 
significantly lower proportion with a median SMA titre of <1:40 (41.8% vs 53.8%, p=0.006) 
when compared to patients with CEHAID.  
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There were, however, no significant differences between AIH patients with and 
without CEHAID pertinent to treatment modality utilised, treatment responses, number of 
relapses and long term clinical outcomes including disease progression, development of HCC 
and episodes of decompensation leading to LT and liver-related death during the follow-up 
period (Table 5). There was also no significant difference in survival between AIH patients 
with and without CEHAID (p = 0.563 by log-rank comparison) (Figure 2). Although 
univariate analysis revealed ascites and INR as one of the variables associated with reduced 
survival, serum albumin at presentation appeared to be an independent predictors of reduced 
survival following multivariate anlaysis (Table 6). 
 
Discussions 
 
This is hitherto the largest cohort study to systematically interogate the patterns and 
clinical impact of CEHAID in patients with AIH. Akin to cohort studies from Italy and 
Germany (14,15), we recorded a high frequency of CEHAID in AIH (42%), with AITD being 
the commonest (18%). Additionally, we found that hypothyroidism was more commonly 
diagnosed than hyperthyrodism and this seemed to be influenced by the type of AIH. Another 
interesting finding was that autoimmune skin diseases were more frequently associated with 
AIH-2 than AIH-1. However, this association was not evident in a South American study 
(13). On the contrary, the prevalence of skin diseases in our study was comparable to the 
report by Homberg et al. describing a cohort of LKM positive AIH patients of North 
European ancestry (21.9% vs. 27.2%)(23). Coeliac disease was found in 1.4% of our AIH 
pateints. This finding accords with the frequency reported in a German study (1.1%) (15) but 
slightly lower than the reports from the Italian and Dutch groups (3.5% and 2.8%, 
respectively) (14,24).   
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Interestingly, our data showed that AIH patients with CEHAID tended to present less 
often with ascites and coagulopathy at presentation compared to patients without CEHAID. 
In addition, they were more often had mild fibrosis on histology at diagnosis. Our study is the 
first to observe this clinical association. There may be two possible hypotheses. Firstly, the 
presence of CEHAID could have led to an early diagnosis of AIH and rendered a “protective” 
effect. This was supported by the observation that more than half of the CEHAID predated 
AIH diagnosis and there was no significant difference pertinent to the histological severity 
and the clinical course or outcome between the two groups of patients. However, the time 
from the first onset of symptoms or first detection of liver dysfunction to the formal diagnosis 
of AIH was similar irrespective of presence of CEHAID. Due to the retrospective nature of 
this study, whether or not the respective subspecialists would monitor liver functions during 
follow-up with CEHAID or suspect AIH on first abnormal liver dysfunction and refer to 
hepatologist remains a potential limiting factor which may lead to inaccurate estimate of the 
time to diagnosis of AIH. 
 
Secondly, AIH patients with CEHAID, on the contrary, could have a more aggressive 
phenotype as they were more likely to have advanced fibrosis (stage 3 and 4) at diagnosis 
compared to AIH patients wthout CEHAID (158/200, 79% vs. 81/134, 60.4%, p<0.001) 
(Table 4). Nevertheless, there was no difference between fibrosis stage 3 and 4 patients with 
or without CEHAID in terms of death/LT (19/66, 28.2% vs. 45/137, 32.8%, p=0.560), HCC 
development (4/66, 6.1% vs. 7/137, 5.1%, p=0.751), disease progression (30/63, 47.6% vs. 
54/142, 38%, p=0.198) and overall survival (p=0.575 by log rank comparison) (data not 
shown). Furthermore, Cox-regression model for survival analysis using univariate and 
multivariate analysis demonstrated that neither presence of cirrhosis, ascites nor prolonged 
INR at diagnosis as the independent predictor for reduced survival (Table 6). Therefore, 
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though the clinical phenotype for AIH patients with CEHAID appears aggressive at 
presentation, it does not seem to portend poor clinical outcomes.  
In a recent study by Muratori et al., more altered liver biochemistry i.e higher serum 
bilirubin and tramsaminitis, was observed in AIH patients without CEHAID, but no statistical 
significance was attained (14). It is worth noting that there was no documentation of 
coagulation profile, occurrence of ascites and fibrosis stage in their report. They noted that 
AIH patients with CEHAID tended to be asymptomatic at presentation and they attributed 
this to a more closer monitoring in this group of patients for other autoimmune diseases, 
therefore any liver related complications could be detected earlier and associated with 
ascertainment bias. This could provide a possible account for our findings but we did not 
observe more asymtomatic patients associated with CEHAID in our cohort. 
Whether or not the presence of CEHAID could be a “protective” mechanism to a 
more aggressive clinical phenotype in AIH at presentation remains to be elucidated. 
Nonetheless, this clinical observation may shed light on the intriguing interplay between the 
shared genetic predisposition of CEHAID and the clinical manifestation of AIH at initial 
presentation.  
The other interesting finding in our study is that SMA positive AIH patients had a 
lower prevalence of CEHAID than SMA negative patients. It is noteworthy that in another 
UK population study with PBC, AMA positive PBC patients were also reported to have a 
significantly lower prevalence of an additional autoimmunity than AMA negative patients 
(25). SMA reactivity in titre >1:80 was reported to be associated with evidence of 
histological disease activity before treatment in a study of 117 patients with AIH (26). 
However, in our study, the higher prevalence of SMA reactivity in a titre of >1:80 in AIH 
patients without CEHAID did not translate to a more severe histological inflammation when 
compared to patients with CEHAID.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Joint pain has been well-documented as an extrahepatic symptom in 10-60% of AIH 
patients at index presentation (1,16,27,28). Arthralgia was reported in 5.2% of our AIH 
patients. It was the only symptom that was more common in isolation in AIH patients with 
CEHAID. This is potentially contributed by the presenting symptoms of the concomittant 
rheumatological diseases as one of the associated CEHAID. In this study, we also 
demonstrated that CEHAID tended to cluster in female patients. Except for a South American 
study in which they found no gender predilection for the association of CEHAID (13), our 
finding was in congruence with previous studies (14,16,29,30). The difference may be 
accounted for by the modulation of immune systems by both the hypothalamic-pituitary-
gonadal system and sex hormones whereby androgens and oestrogens suppress and enhance 
immunity, respectively (31). 
It is well-recognised that patients with autoimmune disease are prone to having 
additional autoimmune conditions affecting different organs, which may coexist in individual 
patients and their families (25,32). Indeed, the coexistence of concomittant personal or family 
autoimmunity confers a score of +1 and +2 in the the original and revised IAIHG scoring 
systems respectively (4,5). In our study, 16.2% of AIH patients had family history of 
CEHAID in first degree relatives, which was in parallel with our previous report with 234 
AIH patients (19.6%) (18), but relatively lower when compared to other studies by Van 
Gerven et al. and Gregory et al. (42% and 43% respectively) (16,17). However, more 
importantly, we reported that a significantly higher proportion of AIH patients who had a 
positive family history of CEHAID, had concurrent extrahepatic autoimmunity in their 
personal history when compared to the counterparts without family history of CEHAID. This 
association was significantly more evident in first degree relatives than second degree 
relatives. However, the results may be limited by the retrospective nature of this study 
whereby the detail documentation of the personal and familial history of CEHAID depends 
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on individual physicians’ discretion.  This may potentially lead to underestimate of the real 
frequency in this cohort. Nevertheless, to our knowledge, this is the first study to demonstrate 
the close link between personal and familial extrahepatic autoimmunity in an AIH cohort and 
emphasize the pivotal role of personal and family history of CEHAID in the IAIHG scoring 
system.  
 
Conclusions 
In this study, we have confirmed strong association of extrahepatic autoimmunity in 
patients with AIH. Recognition of CEHAID is important since it may reflect specific disease 
phenotypes and serves as a clue for subsequent diagnosis of AIH. Moreover, this study 
reinforces the close association of extrahepatic autoimmunity among AIH patients and their 
family. Interestingly, in this study, AIH patients with CEHAID were found to have a lower 
prevalence of SMA reactivity, less ascites and coagulopathy and milder degree of fibrosis on 
histology at diagnosis. Although these do not seem to have notable impact on the clinical 
outcomes of AIH, further evaluation may be warranted to delineate the intricate interplay 
between extrahepatic autoimmunity and the heterogeneity of clinical phenotype in AIH.  
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Table 1. Frequency of CEHAID in AIH patients.  
CEHAID  Frequency, n=562  
Autoimmune thyroid disease 101 (18%) 
     Hypothyroidism* 79 (14.1%) 
     Hyperthyroidism† 22 (3.9%) 
Type 1 diabetes mellitus 21 (3.7%) 
Connective tissue disorders 69 (12.3%) 
Rheumatoid arthritis 19 (3.4%) 
Systemic lupus erythematosus 16 (2.8%) 
Sjogren’s syndrome 16 (2.8%) 
Serongative polyarthropathy 8 (1.4%) 
Autoimmune skin disease 45 (8%) 
Vitiligo 6 (1%) 
Alopecia areata 6 (1%) 
Gastrointestinal disorders 33 (5.9%) 
Ulcerative colitis 21 (3.7%) 
Coeliac disease 8 (1.4%) 
Hematological disorders 14 (2.5%) 
Idiopathic thrombocytopenic purpura 7 (1.2%) 
Lung disorders 8 (1.4%) 
Pulmonary fibrosis 3 (0.5%) 
Neurological diseases 5 (0.9%) 
Multiple sclerosis 2 (0.4%) 
Renal disease 4 (0.5%) 
lupus nephritis 1 (0.2%) 
Miscellaneous  
Raynaund’s phenomenon 9 (1.6%) 
* Hashimoto’s thyroiditis (78 patients) and myxedema (1 patient). 
† Grave’s disease (19 patients) and toxic multinodular goitre (3 patients).  
Table 2. Patterns and frequency of CEHAID in AIH patients based on the serological types¶ 
 
 
CEHAID AIH-1 
(n=459) (%) 
AIH-2 
(n=32) (%) 
Autoantibody 
negative AIH 
(n=56) (%) 
P-value 
AITD 73 (15.9) 10 (31.3) 18 (32.1) 0.025*/0.003†/NS‡ 
Hypothyrodism 59 (12.9) 6 (18.8) 14 (25) 0.014†/NS*,‡ 
Hyperthyroidism 14 (3.1) 4 (12.5) 4 (7.1) 0.024*/NS†,‡ 
Type1 DM 17 (3.7) 1 (3.1) 3 (5.4) NS*,†,‡ 
IBD 23 (5) 0  1 (1.8) NS*,†,‡ 
Coeliac disease 6 (1.3) 1 (3.1) 1 (1.8) NS*,†,‡ 
SJS 15 (3.3) 1 (3.1) 0  NS*,†,‡ 
RA 18 (3.9) 0  1 (1.8) NS*,†,‡ 
SLE 15 (3.3) 1 (3.1) 0  NS*,†,‡ 
Skin disease 32 (7) 7 (21.9) 4 (7.1) 0.009*/NS†,‡ 
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AIH, autoimmune hepatitis; AITD, autoimmune thyroid disease; CEHAID, concurrent 
extrahepatic autoimmune disease; DM, diabetes mellitus; IBD, inflammatory bowel disease; 
RA, rheumatoid arthritis; SJS, Sjogren’s syndrome; SLE, systemic lupus erythematosus 
 
NS, not significant (p>0.05); Values in bold are significant (p<0.05). 
 
*
 P-value for AIH-1 vs. AIH-2. 
†
 P-value for AIH-1 vs. autoantibody negative AIH. 
‡ P-value for AIH-2 vs. autoantibody negative AIH. 
¶ 15 patients with missing data for autoantibodies were excluded for analysis. 
 
Table 3. Comparison of demographics, mode of onset and presenting signs and symptoms 
between AIH patients with and without CEHAID  
 
 AIH with CEHAID 
(n=236) 
AIH without CEHAID 
(n=326) 
 P-value 
Age at diagnosis (years) 46 (2-85) 42 (5-82) 0.200 
Female, n (%) 201(85.2) 248(76.1) 0.008 
Caucasian, n (%) 203 (86) 270 (82.8) 0.306 
African-carribean, n (%) 21(8.9) 26 (8) 0.679 
Asian, n (%) 8 (3.4%) 18 (5.5%) 0.235 
Follow-up duration (months) 120 (1-544) 124 (0.25-532) 0.948 
Time to diagnosis (months) 3 (0.25-180) 3 (0.25-216) 0.832 
Post treatment IAIHG score 22 (11-28) 20 (11-28) <0.001
Definite/Probable AIH 203/33 252/74 0.009 
AIH-1/AIH-2/ Autoantibody 
negative 
190/17/26 269/15/30 0.357 
Mode of onset    
Acute 132/221(59.7%) 182/294 (61.9%) 0.616 
Insidious 50/221(22.6%) 60/294 (20.4%) 0.543 
Asymptomatic 39/221(17.6%) 52/294 (17.6%) 0.991 
Cirrhosis at diagnosis* 72/232 (31%) 115/323 (35.6%) 0.261 
Child-pugh score, median 
(range) 
7 (5-11) 
 
7 (5-13) 
 
0.177 
Signs and symptoms at 
index presentation 
   
Malaise/lethargy 90/221 (40.7%) 128/295 (43.4%) 0.544 
Dark urine/pale stool 60/221 (27.1%) 96/295 (32.5%) 0.187 
Joint pain 18/221 (8.1%) 9/295 (3.1%) 0.010 
Pruritus 26/221 (11.8%) 43/295 (14.6%) 0.353 
Rash 15/221 (6.8%) 11/295 (3.7%) 0.116 
Abdominal pain 57/221 (25.8%) 68/295 (23.1%) 0.472 
Jaundice 127/221 (57.5%) 181/295 (61.4%) 0.373 
Ascites 14/221 (6.3%) 40/295 (13.6%) 0.008 
Hepatic encephalopathy 4/221(1.8%) 6/295 (2%) 0.855 
Hematemesis 5/221 (2.3%) 9/295 (3.1%) 0.585 
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AIH, autoimmune hepatitis; GI, gastrointestinal; IAIHG, International Autoimmune Hepatitis 
Group. 
*Based on histology and/or imaging studies 
Values in bold are significant (p<0.05).  
Table 4. Comparison of biochemical, immunological, hematological parameters and 
histology at diagnosis between AIH patients with and without CEHAID   
 
 AIH with CEHAID 
(n=236) 
AIH without 
CEHAID (n=326) 
P-value 
AST, (IU/L) (NR<50) 591(23-4603) 616 (19-3482) 0.605 
ALP (IU/L) (NR<130) 196 (67-3588) 184 (23-1677) 0.286 
ALP/AST ratio 0.374 (0.03-9.96) 0.371 (0.03-6.80) 0.063 
Bilirubin (mmol/L)(NR 5-17)  59 (5-1208) 73.5 (5-1096) 0.196 
GGT (IU/L) (NR5-50) 150 (27-3410) 171 (8-1131) 0.213 
Albumin (g/L) (NR 35-42) 35 (19-55) 34 (18-48) 0.106 
Globulin (g/L) 44.5 (17-96) 46 (14-105) 0.133 
Peak IgG (g/L) (NR<18) 24.9 (4.6-70.7) 26.5 (4-89.5) 0.561 
INR (NR 0.8-1.2) 1.18 (0.80-3.13) 1.27 (0.87-2.62) 0.013 
Creatinine (µmol/L)  
(NR 53-106) 
74 (43-210) 72 (38-176) 0.805 
Sodium (mmol/L)  
(NR136-145) 
137 (126-143) 137 (80-144) 0.598 
Peak ANA 80 (0-10240) 40 (0-5120) <0.001 
ANA positivity 163/237 (68.8%) 209/325 (64.3%) 0.519 
SMA positivity 111/223 (49.8%) 203/312 (65.1%) <0.001 
Peak SMA  0 (0-2560) 40 (0-10240) 0.128 
SMA titre <40 120/223 (53.8%) 130/312 (41.8%) 0.006 
SMA titre >80 67/223 (30%) 128/312 (41.2%) 0.009 
LKM positivity 17/233 (7.3%) 16/316 (5.1%) 0.197 
Histology 
(Severity of inflammation)* 
   
Grade <3 31/197 (15.7%) 40/274 (14.6%) 0.734 
Grade 3 60 /197 (30.5%) 80/274 (29.2%) 0.768 
Grade 4  106/197 (53.8%) 154/274 (56.2%) 0.606 
Histology (fibrosis score)†    
Stage 0  5/134 (3.7%) 9/200 (4.5%) 0.731 
Stage 1 28/134 (20.9%) 13/200 (6.5%) <0.001 
Stage 2 20/134 (14.9%) 20/200 (10%) 0.174 
Stage 3 38/134 (28.4%) 82/200 (41%) 0.018 
Stage 4 43/134 (32.1%) 76/200 (38%) 0.269 
Stage 3 + 4 81/134(60.4%) 158/200 (79%) <0.001 
 
ALP, alkaline phosphatase; ANA, antinuclear antibody; AST, aspartate aminotransferase; 
GGT, gamma glutamyl transferase; INR, international normalized ratio; LKM, liver-kidney- 
microsomal antibody; NR, normal range; SMA, smooth muscle antibody.  
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Values in bold are significant (p<0.05).  
 
*91 patients with missing data were excluded from analysis. 
 
†228 patients with either missing data or uncertain fibrosis stage due to severe multi-acinar or 
panacinar collapse, were excluded from analysis. 
 
Table 5. Comparison of treatment, response to therapy and clinical outcomes in AIH patients 
with and without CEHAID  
 
 AIH with CEHAID 
(n=236) 
AIH without CEHAID 
(n=326) 
P-value 
Initial therapy    
Prednisolone alone 190/233 (81.5%) 243/320 (75.9%) 0.114 
Prednisolone + 
Azathioprine 
37/233 (15.9%) 63/320 (19.7%) 0.251 
Others* 6/233 (2.6%) 14/320 (4.4%) 0.263 
Maintenance therapy    
Prednisolone alone 37/224 (16.5%) 39/311 (12.5%) 0.194 
Prednisolone + 
Azathioprine 
70/224 (31.3%) 107/311 (34.4%) 0.444 
Azathioprine 66/224 (29.5%) 111/311 (35.7%) 0.131 
Others† 29/224 (12.9%) 27/311 (8.7%) 0.112 
Off therapy 22/224 (9.8%) 27/311 (8.7%) 0.652 
Response to treatment 
and relapses 
   
Complete response 216/231 (93.5%) 299/316 (94.6%) 0.584 
Partial response 10/231 (4.3%) 9/316 (2.8%) 0.350 
No response 5/231 (2.2%) 8/316 (2.5%) 0.781 
One relapse 39/212 (18.4%) 60/300 (20%) 0.651 
≥2 relapses 46/212 (21.7%) 76/300 (25.6%) 0.342 
Clinical outcomes¶    
Disease progression 69/194 (35.6%) 91/271 (33.6%) 0.656 
HCC 7/194 (3.6%) 13/263 (4.9%) 0.491 
Total LTX/death 43/194 (22.2%) 71/263(27%) 0.238 
Liver-related death‡/LT 28/39 (71.8%) 40/69 (58.0%) 0.153 
 
HCC, hepatocellular carcinoma; LT, liver transplantation. 
*Second-line therapy such as tacrolimus, mycophenolate mofetil or cyclosphosphamide. 
†Different combinations of prednisolone, tacrolimus, mycophenolate mofetil and 
azathioprine.  
‡Etiology of death for 6 patients were uncertain. 
¶105 patients who had lost to follow-up were excluded from analysis. 
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Figure 2.  Survival curve of AIH p
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